Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis

  title={Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis},
  author={Farhad Jadidi-Niaragh and Abbas Mirshafiey},

Histamine and neuroinflammation: insights from murine experimental autoimmune encephalomyelitis

Evidence of the complex and controversial role of histamine in the pathogenesis of MS and EAE is reviewed and the therapeutic potential of histaminergic ligands in the treatment of autoimmune diseases is evaluated.

The Histamine and Multiple Sclerosis Alliance: Pleiotropic Actions and Functional Validation.

How a long-standing molecule with previously recognized immunomodulatory and neuroprotective functions, histamine, might still provide a renewed and far-reaching role in MS is reported on.

Central Nervous System Anti-Inflammatory Responses within the Regulatory Cell Frequency and Facilitates Receptor Optimizes T 4 Histamine H

Compared with wild-type mice, animals with a disrupted Hrh4 (H 4 RKO) develop more severe myelin oligodendrocyte glycoprotein (MOG) 35–55 -induced experimental allergic encephalomyelitis and Mechanistically, it is shown that H 4 R plays a role in determining the frequency of T regulatory cells in secondary lymphoid tissues, and regulates T R cell chemotaxis and suppressor activity.

Histamine H4 Receptor Optimizes T Regulatory Cell Frequency and Facilitates Anti-Inflammatory Responses within the Central Nervous System

It is shown that, compared with wild-type mice, animals with a disrupted Hrh4 (H4RKO) develop more severe myelin oligodendrocyte glycoprotein (MOG)35\x{2013}55-induced experimental allergic encephalomyelitis and the lack of H4R leads to an impairment of an anti-inflammatory response.

Serum levels of histamine and diamine oxidase in multiple sclerosis.

The research team found significant low levels of histamine and diamine oxidase in RRMS patients; however the pathogenesis of this issue was unclear.

Type 2 Inflammatory Responses in Autoimmune Demyelination of the Central Nervous System: Recent Advances

The most recent developments showing the involvement of type 2 inflammatory components in CNS autoimmunity are summarised and possible lines of further investigation are discussed.

The Role of Autoantibodies in Diagnosis of Multiple Sclerosis

The most significant autoantibodies which could be used as biomarkers for diagnosis, prognosis and treatment in MS are discussed and the hope is that biomarkers speed up the MS monitoring.

Immethridine, histamine H3-receptor (H3R) agonist, alleviated experimental autoimmune encephalomyelitis via inhibiting the function of dendritic cells

The treatment of immethridine was used to treat Experimental autoimmune encephalomyelitis (EAE) and its therapeutic effect was evaluated, showing that the treatment ofimmethridines could alleviate EAE.

New kid on the block: does histamine get along with inflammation in amyotrophic lateral sclerosis?

Results from amyotrophic lateral sclerosis (ALS) patients and pre-clinical studies strongly suggest that systemic and CNS-intrinsic immune activation plays a central role in ALS pathogenesis.

Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis

Possible roles of gastric acid inhibitors on immunopathogenic mechanisms associated with multiple sclerosis are reviewed.



Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS

It is reported that, compared with wild-type animals, mice with a disrupted HA H3 receptor (H3RKO) develop more severe disease and neuroinflammation and it is shown that this effect is associated with dysregulation of blood–brain barrier permeability and increased expression of MIP-2, IP-10, and CXCR3 by peripheral T cells.

The role of histamine H4 receptor in immune and inflammatory disorders

The available data strongly point to the H4 receptor as a novel target for the pharmacological modulation of histamine‐transferred immune signals and offer an optimistic perspective for the therapeutic exploitation of this promising new drug target in inflammatory disorders.

The histamine H4 receptor in autoimmune disease

H4R antagonists have been shown to have anti-inflammatory properties and efficacy in a number of disease models, such as those for asthma and colitis in vivo and may be useful in treating autoimmune diseases in addition to allergy.

Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination

It is demonstrated that, in the animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), mediated by T helper 1 (Th1) T cells, histamine receptor 1 and 2 (H1R and H2R) are present on inflammatory cells in brain lesions.

Activation of histamine H2 receptors ameliorates experimental allergic encephalomyelitis

Dimaprit treatment significantly reduced clinical signs compared to vehicle in both C57BL/6 and iNOS deficient EAE mice and significantly reduced CNS staining for lectin-positive macrophages and decreased extravasated albumin staining, an indicator of blood–brain barrier leakage.

A Key Regulatory Role for Histamine in Experimental Autoimmune Encephalomyelitis: Disease Exacerbation in Histidine Decarboxylase-Deficient Mice1

Endogenous histamine appears to regulate importantly the autoimmune response against myelin and the expression of EAE, in this model, and to limit immune damage to the CNS.

Corticotropin-releasing hormone and the blood-brain-barrier.

Acute stress shortens the time of onset of experimental alleric encephalomyelitis that does not develop in W/W mast cell deficient or CRH -/- mice, and brain mast cell inhibition and CRHR antagonists offer novel therapeutic possibilities.

Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation.

Histamine in health and disease.

The realization that first-generation antihistamines often had mixed pharmacological properties and crossed the blood-brain barrier led to the development of the second-generation drugs, which are more selective for H1-receptors, have less access to the central nervous system, and, therefore, a more favorable benefit-to-risk ratio (therapeutic index).

A Pilot, Open Label, Clinical Trial Using Hydroxyzine in Multiple Sclerosis

Hydxyzine could be used as an adjuvant in MS, but the small number of patients enrolled and the short duration of the study precludes any definitive conclusions.